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Abstract
Pleural effusion occurs when formation and accumulation of pleural fluid exceeds its 
absorption. It indicates an imbalance between pleural fluid formation and its removal. 
Pleural fluid accumulates in settings of increased hydrostatic pressure, increased vas-
cular permeability, decreased oncotic pressure, increased intrapleural negative pressure 
and decreased lymphatic drainage. On the basis of pathophysiology, pleural effusion can 
be transudates or exudates. It is important to establish an accurate etiological diagnosis 
so that the patient may be treated in a rational manner. Using Light’s criteria may need 
other extra investigations to differentiate transudates and exudates but using pleural 
fluid cholesterol (pCHOL) will help to diagnose them with only the pleural fluid analy-
sis. Moreover the albumin or protein gradient will need serum as well as the pleural 
fluid investigations and will have more financial burden than just investigating pleural 
fluid cholesterol. Pleural cholesterol is thought to be derived from degenerating cells and 
vascular leakage from increased permeability. Thus pleural fluid cholesterol is one of the 
important investigations that can distinguish exudates from transudates. Routine use of 
pleural fluid cholesterol for classifying pleural effusion should be encouraged to improve 
the accuracy, sensitivity and specificity.
Keywords: pleural effusion (PE), pleural fluid cholesterol (pCHOL), transudates, 
exudates, pleural fluid lactate dehydrogenase (pLDH), serum lactate dehydrogenase 
(sLDH), congestive heart failure (CHF)
1. Introduction
Pleurae are the continuous membranes of the serous pleural sac that invest and enclose 
the lungs. They are called parietal and visceral pleura. The visceral pleura is also called the 
pulmonary pleura that closely covers the lung and is adherent to its surfaces. The parietal 
pleura adhere to the diaphragm, mediastinum and the wall of the thorax. It consists of costal 
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pleura, mediastinal pleura, diaphragmatic pleura and cervical pleura. The pleural space lies 
between the lung and the chest wall and is bounded by the parietal and visceral membranes. 
It contains a thin layer of fluid that serves as a coupling system called pleural fluid. A pleural 
effusion (PE) is present when there is an excess fluid in the pleural space. It indicates an imbal-
ance between pleural fluid formation and its removal. It is important to establish an accurate 
etiological diagnosis so that the patient may be treated in a rational manner.
The pleural space is a real, not potential, space that is approximately 10–20 μm wide and 
extends completely around the lung to the hilar root [1, 2]. When air or fluid collects between 
the two layers, the pleural cavity expands. The schematic diagram for pleural cavity and 
pleurae is in Figure 1.
Pleural fluid is formed from the systemic vessels of the pleural membranes at an approximate rate 
of 0.6 ml/h and is absorbed at a similar rate by the parietal pleural lymphatic system. Normally, 
the pleural spaces contain approximately 0.25 ml/kg of low protein liquid. Disturbances in 
either formation or absorption result in the accumulation of excess pleural fluid [3].
The volume of pleural fluid is small, approximately 0.1–0.2 ml/kg in different studies. From 
parietal pleural capillaries, there is constant movement of fluid into the pleural space at a rate 
of 0.01 ml/kg bodyweight/h. There is a balance of the formation (entry) and absorption (exit) 
of the pleural fluid. The resultant homeostasis leaves 5–15 ml of fluid in the normal pleural 
space [4]. For pleural effusion to be there must be an increase in entry rate or a reduction in 
exit rate.
The parietal pleura has a hydrostatic pressure similar to that of the systemic circulation (30 cm 
H2O), whereas that of the visceral pleura depends on the pulmonary circulation (10 cm H2O). Oncotic pressure is similar in both (25 cm H2O), but the pressure within the pleural cavity is affected by the gravity gradient. Thus, the pleural space is heterogeneous with a nonde-
pendent portion in which Starling forces favor outpouring of fluid into the cavity and the 
parenchymal capillaries [5].
2. Pathophysiology
The mechanism of pleural liquid formation is that the liquid originates from the systemic 
vessels of the pleural membranes, not from the pulmonary vessels [6]. It means that pleural 
Figure 1. Schematic diagram of pleura and pleural cavity.
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liquid is interstitial fluid of the systemic pleural microvessels. There are three major consider-
ations that support this hypothesis [7]:
i. The systemic vessels (of both parietal and visceral pleural membranes) are adjacent to the 
pleural space and are much closer to the pleural space than are the pulmonary vessels.
ii. The low pleural liquid protein concentration (1 g/dl) and ratio to the plasma protein con-
centration (0.15 g/dl) are consistent with a filtrate from high-pressure systemic vessels. 
Large particles will be sieved and relatively restrained compared to the liquid if liquid 
and protein are filtered at high-pressure and high flow across a semi permeable mem-
brane. Thus, plasma proteins, being large, will be retarded much more than the liquid in 
their movement across a membrane, and the protein concentration of the resultant filtrate 
will be low. On the other hand, if liquid and protein are filtered at low pressure and low 
flow, proteins are retarded less, and the protein concentration of the resultant filtrate 
is higher. Filtrates from low-pressure pulmonary vessels, e.g., lung lymph, have a high 
protein concentration (4.5 g/dl) and ratio (0.7) compared to filtrates from systemic vessels 
and to pleural liquid. Of note in this argument, pleural liquid formation is described as 
high flow, whereas its measured rate is relatively slow (0.01 ml/kg/h). However, it is 
the filtration at the systemic microvessels that is described as high as or at least higher 
than filtration across pulmonary microvessels. Some of that filtrate is reabsorbed into 
the low-pressure post capillary venules, and some is removed by bulk flow via the local 
lymphatic vessels. It is only the remainder that then moves into the low-pressure pleural 
space.
iii. In situations where systemic pressure varies, the pleural liquid protein concentration 
varies in concert. For example, systemic hypertensive rats have a lower pleural liquid 
protein-to-plasma protein concentration ratio than do normotensive rats (0.42 versus 
0.55), even though their pulmonary pressures are the same [8]. During development from 
the fetus to the adult, systemic blood pressure generally rises and pulmonary pressure 
falls. In a study in sheep, the pleural protein ratio decreased with development, as would 
be expected if the pleural liquid originated from the high-pressure systemic vessels [9].
2.1. Increased fluid entry
Excess liquid filters out of microvessels based on a balance of hydrostatic and osmotic forces 
across a semi permeable membrane [1, 6]. These forces are well described in the Starling equa-
tion, in which the hydrostatic forces that filter water out of the vessel are balanced by osmotic 
forces that reabsorb water back into the vessel [10, 11].
  Flow = k ×  [ (Pmv − Ppmv) − s  (πmv − πpmv) ] . (1)
In this equation, k is liquid conductance of the microvascular barrier, Pmv and Ppmv repre-
sent hydrostatic pressure in the microvascular and perimicrovascular compartments, respec-
tively, is the reflection coefficient for total protein and ranges from 0 (completely permeable) 
to 1 (completely impermeable), and πmv and πpmv represent protein osmotic pressure in 
microvascular and perimicrovascular liquids, respectively and s is Staverman’s reflection 
coefficient. In normal micro vessels, there is ongoing filtration of a small amount of low pro-
tein liquid. The flow can increase with changes in various parameters of the Starling equation.
Role of Pleural Fluid Cholesterol in Pleural Effusion
http://dx.doi.org/10.5772/intechopen.76370
77
Increase in permeability: An increase in flow can be due to increases in either liquid con-
ductance (an increase in k) or protein permeability (a decrease in reflection coefficient). If the 
endothelial barrier becomes more permeable to liquid and protein, for example, there will be 
an increase in flow of a higher protein liquid. Because absorption does not alter the protein 
concentration of pleural liquid, pleural liquid with a high protein concentration indicates its 
origin from a circulation across an area of increased permeability.
Increase in microvascular pressure: An elevation in venous outflow pressure induces the 
elevation of microvascular pressure (Pmv). Increases in arterial pressure are less likely to be 
transmitted to the microvessels because of the high precapillary resistance and autoregulation 
of arteriolar tone.
Elevations in either systemic venous pressure (affecting the parietal pleura) or pulmonary 
venous pressure (affecting the visceral pleura) can lead to an increase in pleural liquid forma-
tion and the development of a pleural effusion. As vascular permeability is unchanged in this 
setting, the increased flow is associated with a greater sieving of proteins, leading to a filtrate 
with a lower protein concentration than normal (with a pleural liquid-to-plasma protein ratio 
of less than 0.15). Of course, most effusions formed due to increased microvascular pressures, 
i.e., transudative effusions, have a pleural liquid-to-plasma protein ratio much higher than 
this, between 0.4 and 0.5. This fact demonstrates that most liquid must arise from a source 
other than the systemic circulation of the pleural membranes. The likely source is the large 
non-systemic circulation adjacent to the pleural space, namely the pulmonary circulation of 
the nearby lung. In the normal state, lung interstitial liquid, e.g., lymph, filtered from the low-
pressure pulmonary circulation has a protein concentration ratio [12] (lung to plasma protein 
concentration ratio) of 0.7, but with increased flow due to increased pulmonary microvascu-
lar pressures, this ratio falls to 0.4–0.5. This lung interstitial oedema liquid then is the likely 
source of the majority of the hydrostatic pleural effusion [13].
The way lung liquid reach the pleural space is that when the rate of filtrate formation exceeds 
the absorptive capacity of the lung lymphatics, the filtrate accumulates in the peribroncho-
vascular spaces (“cuffs”) [14]. Once in these interstitial spaces, the liquid is not accessible to 
lung lymphatics [15].
Thus, although the lymphatics are undeniably important in removing liquid as it is filtered 
from the pulmonary circulation, they cannot account for the clearance of already established 
oedema from the lung [16]. This interstitial oedema probably leaves the lung by flowing 
down pressure gradients along the interstitial spaces (interlobular septae, peribronchovas-
cular bundles and visceral pleura) of the lung toward either the mediastinum or the pleural 
space. The entry of large amounts of lung interstitial liquid into the pleural space will elevate 
the overall protein concentration of the pleural liquid, giving a ratio of 0.40–0.50, the expected 
range for a transudative effusion [16].
Decrease in pleural pressure: A decrease in pleural pressure, as seen with significant atelec-
tasis, may alter the balance of forces described in the Starling equation by reducing the pres-
sures surrounding the nearby micro vessels. This decrease in perimicrovascular pressures 
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(Ppmv) can enhance filtration across the microvascular barrier of a low protein liquid (with a 
pleural liquid-to-plasma protein ratio of less than 0.15).
Decrease in plasma osmotic pressure: Hypoproteinemia (due to hypoalbuminemia) will 
decrease the plasma oncotic pressure (πmv), thereby increasing the forces favoring filtration 
until the balance is restored. By itself, hypoproteinemia can probably induce small effusions 
with a low protein concentration. In addition, hypoproteinemia can lower the threshold 
for effusion formation when other Starling forces are changed. In a study of hospitalized 
patients with AIDS, for example, hypoproteinemia alone was the apparent cause of 19% of 
all pleural effusions [17]. Together with other factors, a lower plasma protein concentration 
may have contributed to effusion formation in many more patients, because, in general, all 
patients with effusions had a lower plasma albumin concentration than those without effu-
sion (2.5 versus 3.4 g/dl).
2.2. Decreased fluid exit
A decrease in exit rate reflects a reduction in lymphatic function. Because lymphatic function 
is poorly understood, much of this discussion is speculative. Unlike blood vessels, lymphatic 
vessels have one-way valves and propel lymph using both their own rhythmic contractions 
and the respiratory motions of the chest wall. In addition, flow is affected by lymphatic 
patency, availability of liquid, and the pressures influencing filling (pleural pressure) and 
emptying (systemic venous pressure) of lymphatics [18–20].
Intrinsic factors: A number of factors can interfere with or inhibit the ability of lymphatic’s 
to contract, including:
• Cytokines and products of inflammation (e.g., endotoxins)
• Endocrine abnormalities (e.g., hypothyroidism)
• Injury due to radiation or drugs (e.g., chemotherapeutic agents)
• Infiltration of lymphatics by cancer
• Anatomic abnormalities (e.g., yellow nail syndrome)
Extrinsic factors: Multiple extrinsic factors can inhibit lymphatic function although the lym-
phatics themselves are normal. These include:
• Limitation of respiratory motion (e.g., diaphragm paralysis, lung collapse and pneumothorax)
• Extrinsic compression of lymphatics (e.g., pleural fibrosis and pleural granulomas)
• Blockage of lymphatic stomata (e.g., fibrin deposition on pleural surface and pleural 
malignancy)
• Decreased intrapleural pressure (e.g., trapped lung caused by a fibrous rind on the visceral 
pleura)
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Normal pleural fluid resembles water in appearance and clarity, and is odorless [20]. Its 
chemical composition is summarized in Table 1.
Pleural effusion is present when there is excess accumulation of pleural fluid due to its exceed-
ing formation on pleural fluid absorption. At normal circumstances, pleural fluid entering the 
pleural space from the capillaries in the parietal pleura is removed by the lymphatics which 
can absorb 20 times more fluid than is formed.
Fluid can enter the pleural space from the interstitial spaces in the visceral pleura or through 
the diaphragmatic pores from the peritoneal cavity. So pleural effusion will develop in two 
circumstances:
1. When there is excess formation of pleural fluid from parietal pleura, interstitial spaces 
from the lung and peritoneal cavity.
2. When there is inability of removal of pleural fluid by the lymphatics.
Local factors: There is change in the pleural surface permeability due to which the exudative 
pleural effusion occurs.
Systemic factors: There is increase in pulmonary capillary wedge pressure (PCWP) or 
decrease in oncotic pressure that result in alteration of formation and absorption of pleural 
fluid as in transudative pleural effusion.
Translocation of fluid: Small pores in diaphragm act as pathways for peritoneal fluid to enter 
into the pleural cavity as in hepatic hydrothorax. It may be massive even without marked 
ascites.
Parameters Value
Volume 0.1-0.2ml/kg
Cells 1000-5000/mm3
Mesothelial cells 3- 70%
Monocytes 30-75%
lymphocytes 2-30%
Granulocytes 10%
Protein 1-2gm/dl
Albumin /protein 50-70%
Glucose as in plasma
Lactate Dehydrogenase < 50% of plasma
Table 1. Normal composition of pleural fluid.
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The basis in which accumulation of pleural fluid occurs are: increased hydrostatic pressure, 
increased vascular permeability, decreased oncotic pressure, increased intrapleural negative 
pressure and decreased lymphatic drainage.
Pleural effusion may be of two types depending upon the underlying pathology, i.e., tran-
sudative and exudative. The causes of transudative and exudative pleural effusion are sum-
marized in Tables 2 and 3, respectively.
Transudate will be clear fluid with low protein while exudates will have cloudy fluid with 
high protein. Exudates have a ratio of protein in pleural fluid and serum >0.5; ratio of LDH 
in pleural fluid and serum >0.6 and pleural fluid LDH > 2/3rd of upper limit of serum 
LDH. Protein in transudate is less than 2.5 g/dl while exudates have higher values [21].
Transudative pleural effusion is usually due to the increased hydrostatic pressure that is caused 
by congestion in the capillaries, e.g., in heart failure and there is formation of pleural fluid 
from the increased venous pressure of the pleural membranes. However in case of exudates, 
there is vascular leakage of fluid due to increased permeability as a result of inflammation.
1. Increased hydrostatic pressure Congestive Heart Failure
Superior vena cava syndrome
Pericardial effusion
Constrictive cardiomyopathy
Massive pulmonary embolism
2. Decreased capillary Oncotic pressure Cirrhosis of Liver
Nephrotic syndrome
Malnutrition
Protein losing enteropathy
Small Bowel disease
3. Transmission from Peritoneum Any cause of ascites
Peritoneal Dialysis
4. Increased capillary permeability Small pulmonary emboli
Myxoedema
5. Miscellaneous Urinothorax
Acute atelectasis
Wet Beriberi
Idiopathic
Table 2. Transudative pleural effusion.
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1. Respiratory causes Parapneumonic effusion
Tuberculosis
sarcoidosis
Parasitic infections
Pulmonary embolism
Trapped lung
2. Gastrointestinal causes Pancreatitis
Postoperative
Intrabdominal abscesses
Posttransplant of liver
Esophageal perforation
Endoscopic variceal sclerotherapy
3. Cardiac causes Post Myocardial Infarction
Constrictive pericarditis
PostPericardiotomy
4. Occupational Asbestosis
5. Traumatic Hemothorax
6. Post surgical Coronary artery bypass surgery
7. Autoimmune causes Systemic lupus erythematosus
Rhematoid pleurisy
Drug induced lupus
Sjogren syndrome
Wegener’s granulomatosis
Chrug strauss Syndrome
8. Endocrine causes Hypothyroidism
Ovarian hyperstimulation syndrome
9. Renal related Uremia
Peritoneal dialysis
10. Malignancies and complications Mesothelioma
Metastases
Superior vena caval obstruction
11. Drug induced Bromocriptine,Dantrolene, Nitrofurantoin, Amiodarone,etc
12. Lymphatic cause Chylothorax
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3. Clinical features
The clinical features of pleural effusion depend on the amount, the rate of accumulation of 
fluid and the underlying cause. In acute cases, the symptoms appear suddenly. Patients may 
present with shortness of breath, pleuritic pain, cough and constitutional symptoms. Dyspnea 
may result from compression of lung tissue and from mechanical alterations in the respiratory 
muscles as the fluid changes their length-tension relationship. There will be associated symp-
toms related to the etiology of the pleural effusion. So careful elicitation of history in cases of 
pleural effusion may streamline the physician toward the etiological aspect of pleural effusion.
Physical examination reveals decreased respiratory movements on the affected side and dis-
placement of mediastinum to the opposite side. If there is an associated collapse of lung or 
fibrosis, the trachea may be central or may even be pulled to the same side depending on the 
degree of collapse or fibrosis. Tactile fremitus may be decreased to absent but may also be 
increased toward the top of large effusion. Percussion reveals dull to flat note over the fluid.
Auscultation reveals decreased to absent breath sounds but bronchial breath sounds may be 
heard near top of large effusion. Pleural rub can also be heard and sometimes crackles above 
the level of effusion. Frequently, there are E to A changes (egobronchophony) at the upper 
fluid border where underlying lung parenchyma is compressed.
4. Diagnostic clues for exudates from transudates
Light et al. in 1972 found a criteria to have sensitivity and specificity of 99% and 98%, respec-
tively, for differentiating transudative and exudative PE (ratio of protein in pleural fluid and 
serum >0.5; ratio of LDH in pleural fluid and serum >0.6 and pleural fluid LDH > 2/3rd of 
upper limit of serum LDH) [21]. But the other investigators could only reproduce specificities 
of 70–86% using light’s criteria. Also it is found that 25% of patients with transudates pleural 
effusion are mistakenly identified as having exudative effusion by Light’s criteria.
Most transudates have absolute total protein concentrations below 3.0 g/dl (30 g/l), although 
acute diuresis in heart failure can elevate protein levels into the exudative range [22–24].
If one or more of the exudative criteria are met and the patient is clinically thought to have 
a condition producing a transudative effusion, the difference between the protein levels in 
13. MISCELLANEOUS Amyloidosis
Iatrogenic injury
Radiation therapy
Yellow nail syndrome
Table 3. Exudative pleural effusion.
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the serum and the pleural fluid should be measured. If this gradient is >31 g/l (3.1 g/dl), the 
exudative categorization by these criteria can be ignored because almost all such patients 
have a transudative pleural effusion [25]. About only 75% of cases, the etiology of pleural 
effusion can be established with the clinical presentation, biochemical parameters and fluid 
cytology. Despite extensive diagnostic work up in about 20% of pleural effusion, the etiology 
remains unknown [26].
From meta-analysis, Heffner et al. has identified pleural effusion of exudative type with at 
least one of the following condition [27]:
• Pleural fluid protein >2.9g/dl
• Pleural fluid cholesterol >45 mg/dl (1.16 mmol/l)
• Pleural fluid LDH > 2/3rd of upper limit of serum
Roth et al. [28] found that despite the high sensitivity of Light’s criteria (100%), these criteria 
had a low specificity (72%). Using an albumin gradient of 1.2 g/dl or less to indicate exudates 
and greater than 1.2 g/dl to indicate transudates, 57 of the 59 patients (41 exudates; 18 transu-
dates) were correctly classified. Two patients with malignant effusions were misclassified as 
having transudates.
In 2003 National medical journal of India, one article published by Guleria R of AIIMS, New 
Delhi [29] found that for exudative pleural effusion, pleural fluid cholesterol ≥60 mg/dl has 
92% accuracy, 88% sensitivity and 100% specificity; however, Light’s criteria was 98% sensi-
tive and 80% specific.
Evaluation through pleural fluid cholesterol only can avoid the financial burden and double 
pricks (serum and pleural fluid) in anxious patients to go through the series of tests to confirm 
the exudative pleural effusion.
In a study done in Nepal by Hamal et al. [30], pleural fluid cholesterol (pCHOL) is highly 
correlated than protein ratio (pleural fluid protein/serum protein) with clinical diagnosis for 
exudates. It is found that in transudates, parapneumonic, tubercular and neoplastic pleural 
effusion, pCHOL levels were 0.53 ± 0.28, 1.81 ± 0.59, 2.08 ± 0.58 and 1.58 ± 0.65 mmol/l, respec-
tively. With a classifying threshold of 1.16 mmol/L, pCHOL has a sensitivity of 97.7% and 
specificity of 100% for diagnosis of exudates with accuracy of 98.3%.
Pleural cholesterol is thought to be derived from degenerating cells and vascular leakage from 
increased permeability. Though the cause of the rise in cholesterol levels in pleural exudates 
is unknown, two possible explanations have been put forward.
According to the first, the cholesterol is synthesized by pleural cells themselves for their own 
needs [31] (extrahepatic synthesis of cholesterol is now known to be much greater than was 
once thought, depends on the metabolic needs of cells, and is in dynamic equilibrium with 
cholesterol supply by LDL and cholesterol removal by HDL) [32] and the concentration of 
cholesterol in pleural cavity is increased by the degeneration of leukocytes and erythrocytes, 
which contain large quantities.
Cholesterol - Good, Bad and the Heart84
The second possible explanation is that pleural cholesterol derives from plasma; some 70% 
of plasma cholesterol is bound to low density, high molecular weight lipoproteins (LDL) and 
the rest to HDL or very low density lipoproteins (VLDL) and the increased permeability of 
pleural capillaries in pleural exudate patients would allow plasma cholesterol to enter the 
pleural cavity.
The cause of the increased cholesterol concentration is unknown, but two hypotheses are 
available [33, 34]: (A) cholesterol production by different cells has been recognized and it is 
possible that destruction of white and red blood cells in pleural effusion can cause an increase 
in the fluid cholesterol level. (B) Increased pleural permeability causes cholesterol concentra-
tions to increase.
Measurement of pleural cholesterol >45 mg/dl has been used to improve the accuracy of dif-
ferentiating transudative and exudative effusion [35].
Another study done in Catholic University hospital, Santiago, Chile [36] Marina Costa found 
sensitivity and specificity of following parameters for exudative pleural effusion as 98 and 
82% (criteria by Light et al.), 90 and 100% (pCHOL >45 mg/dl) and 99 and 98% (by pCHOL+ 
pLDH >200 IU/l), respectively.
A study done by Hamm et al., mean cholesterol level in malignant effusions was 94 mg/dl, 
76 mg/dl in inflammatory effusions and 30 mg/dl in the transudates. Using a dividing line 
of 60 mg/dl to separate the exudates from transudates, only 5% were incorrectly classified. 
Elevated cholesterol levels in exudates seem to be independent of serum levels [34].
Using pleural fluid, cholesterol levels at a cut-off point of greater than 60 mg/dl and/or total 
protein at a cut-off point of greater than 3 g/dl for distinguishing transudates and exudates, 
the sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV), were 100% in a study done by Patel and Choudhury [37].
Brett reviewing Eid et al. CHEST 2002 Nov, most but not all, exudative effusions in CHF 
patients have causes other than heart failure. The authors believe that, in some cases with no 
apparent cause other than CHF, transudates might be `converted’ into exudates by traumatic 
taps (which lead to increased pleural fluid lactate dehydrogenase—itself a criterion for an 
exudate) or by aggressive dieresis (which might transiently increase protein and LDL cho-
lesterol concentrations in pleural fluid). In patients with previous bypass surgery, persistent 
impairment of lymphatic clearance might predispose to exudative effusions [38].
Pleural fluid cholesterol is better than Light’s criteria for the differentiation of transudates and 
exudates and is less cumbersome as it does not require a simultaneous blood sampling. Cut-
off value of pleural fluid cholesterol for differentiating transudates and exudates should be 
45 mg/dl [39]. In this study, the sensitivity, specificity, positive predictive value and negative 
predictive value of the pleural fluid cholesterol (cut-off >45 mg/dl) were 97.06, 94.74, 97.06 and 
94.74%, respectively, for identifying exudates.
NT-proBNP has been shown to correctly diagnose congestive heart failure as a cause of most 
effusions that have been misclassified as exudates by Light’s criteria. Use of this test may 
therefore avoid repeated invasive investigations in patients where there is a strong clinical 
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suspicion of cardiac failure. The cut-off value however, varied widely from 600 to 4000 pg/ml 
(with 1500 pg/ml being most commonly used), and most studies excluded patients with more 
than one possible etiology for their effusion [40].
The findings in a study done by Mehdi Kashmiri showed taking a value of pleural cholesterol 
>55 mg/dl and pleural/serum cholesterol >0.3 to define exudative effusion resulted in less 
erroneous classification with a sensitivity of 93%, a specificity of 100%, a positive predictive 
value (PPV) of 100% and an accuracy of 95.2%. Using Light’s criteria gave a sensitivity of 95%, 
a specificity of 95%, a PPV of 97.6% and an accuracy of 95.2%. Using cholesterol in differenti-
ating exudate from transudate was especially useful in patients with congestive heart failure 
who received diuretics [41].
There are other biochemical parameters other than pleural fluid cholesterol to identify the 
exudative pleural effusions. The difficulties in classifying pleural fluid effusion are wiped 
away with few parameters other than cholesterol.
It has been observed that increase in uric acid level was present in pleural fluid of transudative 
pleural effusion than exudative pleural effusion. The optimum cut-off level for pleural fluid 
uric acid was 5.35 mg/dl with sensitivity of 89.32% and specificity of 92.60% [42]. Increase in 
uric acid in pleural fluid can be regarded to be a manifestation of tissue hypoxia [43]. Most of 
the patients with reasons to produce transudative effusion had oxidative stress or hypoxemia 
to explain the increased uric acid synthesis. The respiratory tract, indeed, remains a major 
target of oxidative damage caused by both endogenous and exogenous processes [44, 45]. 
The major causes of tissue damage associated with chronic inflammatory lung disease are the 
reactive species produced by phagocytes.
Metintas et al. [46] stated that the binding of uric acid is minimal to plasma protein and it is 
diffuse freely to different compartments. They suggested that the increase permeability, due 
to change in pleural-capillary pressure in formation of transudate, is the cause of the increase 
of uric acid levels in pleural fluid. So all these factors explains why uric acid level increases in 
transudative condition than exudative one.
In cases where no cause for an exudative effusion can be identified or CHF suspected, the 
sequential application of the fluid LDH, followed by the serum to pleural fluid protein (SF-
P) and then the serum to pleural fluid albumin (SF-A) gradients, may assist in reclassifying 
pleural effusions as transudates [47].
Leers Mathie P.G. from Netherlands [48] found that combination of the parameters: pleural 
cholesterol and pleural LDH had accuracy of 98%, sensitivity of 98% and 95% specificity for 
diagnosing exudative pleural effusion compared that calculated by light’s criteria being accu-
racy of 93%, sensitivity 100% and specificity 73%.
5. Conclusion
A pleural effusion (PE) is present when there is an excess fluid in the pleural space. It indi-
cates an imbalance between pleural fluid formation and its removal. Pleural fluid is formed 
from the systemic vessels of the pleural membranes at an approximate rate of 0.6 ml/h and is 
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absorbed at a similar rate by the parietal pleural lymphatic system [6]. Pleural fluid accumu-
lates due to local factors, systemic factors or translocation of fluid. At normal circumstances, 
pleural fluid entering the pleural space from the capillaries in the parietal pleura is removed 
by the lymphatics which can absorb 20 times more fluid than is formed.
Pleural fluid accumulates in settings of increased hydrostatic pressure, increased vascular 
permeability, decreased oncotic pressure, increased intrapleural negative pressure and 
decreased lymphatic drainage. On the basis of pathophysiology, pleural effusion can be tran-
sudates or exudates. It is important to classify the pleural fluid for diagnosis and appropriate 
management. Transudates occur when the mechanical factors influencing the formation or 
reabsorption of pleural fluid are altered, like a decrease in plasma or elevated systemic or 
pulmonary hydrostatic pressure. Exudates results from inflammation or irritation or other 
disease processes involving pleura resulting in increased permeability.
Light et al. found criteria to have sensitivity and specificity of 99 and 98%, respectively, for dif-
ferentiating transudative and exudative PEs (ratio of protein in pleural fluid and serum >0.5; 
ratio of LDH in pleural fluid and serum >0.6 and pleural fluid LDH >2/3rd of upper limit 
of serum LDH) [20]. It is found that 25% of patients with transudates pleural effusion are 
mistakenly identified as having exudative effusion by Light’s criteria. In cases of heart failure 
on diuretic therapy, the transudative pleural effusions have high protein. Pleural cholesterol 
is thought to be derived from degenerating cells and vascular leakage from increased perme-
ability. The cause of the increased cholesterol concentration is unknown, but two hypotheses 
are available: one states that cholesterol production by different cells has been recognized 
and it is possible that destruction of white and red blood cells in pleural effusion can cause an 
increase in the fluid cholesterol level and second relates with increased pleural permeability 
that causes cholesterol concentrations to increase.
Pleural fluid cholesterol as proposed by Heffner’s meta-analysis can diagnose exudative pleu-
ral effusion without need of serum values. This can avoid the financial burden and double 
pricks (serum and pleural fluid) in anxious patients to go through the series of tests to confirm 
the exudative pleural effusion. With a classifying threshold of 1.16 mmol/l, pCHOL has a 
sensitivity of 97.7% and specificity of 100% for diagnosis of exudates with accuracy of 98.3% 
compared to Light’s criteria (98% sensitivity and 82% specificity). pCHOL is highly correlated 
than protein ratio with clinical diagnosis for exudates [29]. Moreover in pleural effusion with 
etiologies as transudates, parapneumonic, tubercular and neoplastic pleural effusion, pCHOL 
levels were 0.53 ± 0.28, 1.81 ± 0.59, 2.08 ± 0.58 and 1.58 ± 0.65 mmol/L, respectively.
Study done by Leers Mathie PG, it was found that pleural cholesterol and pleural LDH had 
accuracy of 98%, sensitivity of 98% and 95% specificity for diagnosing exudative pleural effu-
sion compared that calculated by light’s criteria being accuracy of 93%, sensitivity 100% and 
specificity 73% [47].
It is concluded that pCHOL has a better sensitivity, specificity and accuracy in differentiating 
transudates and exudates than the parameters of Light’s criteria. This also avoids the plasma 
protein and gradients, sLDH, pleural fluid protein and LDH. Therefore it is more efficient, 
easier and more cost effective method to differentiate exudates from transudates. This study 
also suggests that determination of pCHOL should be in routine practice in cases of pleural 
effusion.
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